{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Acute GVHD grade 2-4 was assessed in patients in the FluBU and FluMel groups up to 100 days after transplant.","groups":[{"description":"All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.\n\nfludarabine/busulfan: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \\<40%, DLCO\\<50%, LVEF\\<40, Serum bilirubin \\>1.5 mg% or serum transaminases \\> 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.","id":"OG000","title":"Fludarabine/Busulfan + ATG"},{"description":"All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.\n\nfludarabine/ melphalan: All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \\<40%, DLCO\\<50%, LVEF\\<40, Serum bilirubin \\>1.5 mg% or serum transaminases \\> 2x nl).","id":"OG001","title":"Fludarabine/Melphalan +ATG"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 100 days post-transplant (acute GVHD).","title":"Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).","type":"SECONDARY","unitOfMeasure":"participants"}